JP2015517994A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015517994A5 JP2015517994A5 JP2015503640A JP2015503640A JP2015517994A5 JP 2015517994 A5 JP2015517994 A5 JP 2015517994A5 JP 2015503640 A JP2015503640 A JP 2015503640A JP 2015503640 A JP2015503640 A JP 2015503640A JP 2015517994 A5 JP2015517994 A5 JP 2015517994A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- oral dosage
- halofuginone
- pharmaceutically acceptable
- enteric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006186 oral dosage form Substances 0.000 claims description 102
- LVASCWIMLIKXLA-LSDHHAIUSA-N halofuginone Chemical compound O[C@@H]1CCCN[C@H]1CC(=O)CN1C(=O)C2=CC(Cl)=C(Br)C=C2N=C1 LVASCWIMLIKXLA-LSDHHAIUSA-N 0.000 claims description 51
- 229950010152 halofuginone Drugs 0.000 claims description 50
- 150000003839 salts Chemical class 0.000 claims description 41
- SJUWEPZBTXEUMU-LDXVYITESA-N 7-bromo-6-chloro-3-[3-[(2s,3r)-3-hydroxypiperidin-2-yl]-2-oxopropyl]quinazolin-4-one;hydrobromide Chemical compound Br.O[C@@H]1CCCN[C@H]1CC(=O)CN1C(=O)C2=CC(Cl)=C(Br)C=C2N=C1 SJUWEPZBTXEUMU-LDXVYITESA-N 0.000 claims description 24
- 201000006938 muscular dystrophy Diseases 0.000 claims description 18
- 239000002702 enteric coating Substances 0.000 claims description 13
- 238000009505 enteric coating Methods 0.000 claims description 13
- 241000124008 Mammalia Species 0.000 claims description 12
- 229920001577 copolymer Polymers 0.000 claims description 12
- 229920000642 polymer Polymers 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 9
- 230000037396 body weight Effects 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 7
- 239000006201 parenteral dosage form Substances 0.000 claims description 6
- WROUWQQRXUBECT-UHFFFAOYSA-N 2-ethylacrylic acid Chemical compound CCC(=C)C(O)=O WROUWQQRXUBECT-UHFFFAOYSA-N 0.000 claims description 4
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 4
- 206010028813 Nausea Diseases 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 229920001800 Shellac Polymers 0.000 claims description 4
- 206010047700 Vomiting Diseases 0.000 claims description 4
- 206010000059 abdominal discomfort Diseases 0.000 claims description 4
- 239000000835 fiber Substances 0.000 claims description 4
- 125000005395 methacrylic acid group Chemical group 0.000 claims description 4
- 230000008693 nausea Effects 0.000 claims description 4
- 230000036407 pain Effects 0.000 claims description 4
- 239000004208 shellac Substances 0.000 claims description 4
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims description 4
- 229940113147 shellac Drugs 0.000 claims description 4
- 235000013874 shellac Nutrition 0.000 claims description 4
- 230000008673 vomiting Effects 0.000 claims description 4
- 235000013311 vegetables Nutrition 0.000 claims description 3
- 206010010356 Congenital anomaly Diseases 0.000 claims description 2
- 208000023178 Musculoskeletal disease Diseases 0.000 claims description 2
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 2
- 239000003929 acidic solution Substances 0.000 claims description 2
- 239000003637 basic solution Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 230000001815 facial effect Effects 0.000 claims description 2
- 239000006207 intravenous dosage form Substances 0.000 claims description 2
- 230000036470 plasma concentration Effects 0.000 claims description 2
- 239000006203 subcutaneous dosage form Substances 0.000 claims description 2
- 239000001993 wax Substances 0.000 claims 2
- 238000000034 method Methods 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229910001651 emery Inorganic materials 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261617356P | 2012-03-29 | 2012-03-29 | |
| US61/617,356 | 2012-03-29 | ||
| US201361798784P | 2013-03-15 | 2013-03-15 | |
| US61/798,784 | 2013-03-15 | ||
| PCT/US2013/034616 WO2013149148A2 (en) | 2012-03-29 | 2013-03-29 | Dosage forms of halofuginone and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018191024A Division JP2018203790A (ja) | 2012-03-29 | 2018-10-09 | ハロフジノンの剤形およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015517994A JP2015517994A (ja) | 2015-06-25 |
| JP2015517994A5 true JP2015517994A5 (enExample) | 2016-03-03 |
Family
ID=49261398
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015503640A Pending JP2015517994A (ja) | 2012-03-29 | 2013-03-29 | ハロフジノンの剤形およびその使用 |
| JP2018191024A Pending JP2018203790A (ja) | 2012-03-29 | 2018-10-09 | ハロフジノンの剤形およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018191024A Pending JP2018203790A (ja) | 2012-03-29 | 2018-10-09 | ハロフジノンの剤形およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20150086627A1 (enExample) |
| EP (1) | EP2830628A4 (enExample) |
| JP (2) | JP2015517994A (enExample) |
| CN (1) | CN104640546A (enExample) |
| AU (2) | AU2013237881B2 (enExample) |
| CA (1) | CA2869054A1 (enExample) |
| HK (1) | HK1206646A1 (enExample) |
| IL (1) | IL234841A0 (enExample) |
| WO (1) | WO2013149148A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10335573B2 (en) | 2015-12-02 | 2019-07-02 | Cook Medical Technologies Llc | Intraperitoneal chemotherapy medical devices, kits, and methods |
| CN106539754A (zh) * | 2016-11-25 | 2017-03-29 | 河北科星药业有限公司 | 氢溴酸常山酮溶液及其制备方法 |
| AR110963A1 (es) | 2017-02-07 | 2019-05-22 | Dae Woong Pharma | Compuestos heterocíclicos, su método de preparación y composición farmacéutica que los comprende |
| CN109793741B (zh) * | 2019-03-11 | 2021-02-26 | 中国农业科学院兰州兽医研究所 | 一种常山酮在制备预防口蹄疫病毒感染的药物中的应用 |
| US20230321101A1 (en) * | 2020-08-21 | 2023-10-12 | Philip L.S.M. Gordts | Methods and uses of halofuginone |
| CN113880860B (zh) * | 2021-12-08 | 2022-02-22 | 北京肿瘤医院(北京大学肿瘤医院) | 常山酮衍生物及其药物组合物和用途 |
| CN114469956B (zh) * | 2022-01-29 | 2023-07-18 | 中国科学技术大学 | 常山酮在治疗和预防动脉粥样硬化性疾病的药物中的应用 |
| CN116392493A (zh) * | 2023-02-02 | 2023-07-07 | 四川大学华西医院 | 一种关于天然活性化合物hf诱导atc细胞凋亡的应用 |
| CN119215052B (zh) * | 2024-09-03 | 2025-09-02 | 南方医科大学南方医院 | 常山酮在制备治疗异位骨化的药物中的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5512410B2 (enExample) * | 1974-02-27 | 1980-04-02 | ||
| JPS5732230A (en) * | 1980-07-18 | 1982-02-20 | Parke Davis & Co | Instetine-soluble capsule |
| EP0313845A1 (en) * | 1987-09-29 | 1989-05-03 | Warner-Lambert Company | Stabilization of enteric coated dosage form |
| JPH0436237A (ja) * | 1990-06-01 | 1992-02-06 | Taiho Yakuhin Kogyo Kk | 抗腫瘍性複合製剤 |
| JPH04346930A (ja) * | 1991-05-25 | 1992-12-02 | Sumitomo Pharmaceut Co Ltd | 安定なアスピリン腸溶錠 |
| US5356634A (en) * | 1992-11-13 | 1994-10-18 | Eastman Chemical Company | Controlled-release delivery system |
| US20030059471A1 (en) * | 1997-12-15 | 2003-03-27 | Compton Bruce Jon | Oral delivery formulation |
| IL148292A (en) | 2002-02-21 | 2008-08-07 | Shai Yarkoni | Stable preparations of lupoginone and other quinazolinone derivatives |
| JP2006511449A (ja) * | 2002-04-29 | 2006-04-06 | シャイア ラボラトリーズ，インコーポレイテッド | 改良されたバイオアベイラビリティーを有する薬学的処方物 |
| JP4749660B2 (ja) * | 2002-10-16 | 2011-08-17 | 武田薬品工業株式会社 | 安定な固形製剤 |
| CA2504388A1 (en) | 2002-10-31 | 2004-05-13 | State Of Israel, Ministry Of Agriculture | Quinazolinone compositions for regulation of gene expression related to pathological processes |
| WO2004043345A2 (en) * | 2002-11-08 | 2004-05-27 | Kin-Ping Wong | Extract of trapa natans and methods of using the same |
| US7705049B2 (en) * | 2004-01-21 | 2010-04-27 | New York University | Methods for treating non-melanoma cancers with PABA |
| US20050208134A1 (en) * | 2004-02-25 | 2005-09-22 | Shlomo Magdassi | Biocompatible polymeric beads and use thereof |
| US20070281961A1 (en) * | 2006-06-05 | 2007-12-06 | Brite Age | Modified Compositions And Methods For Enhancing Brain Function |
| US8410120B2 (en) | 2007-01-21 | 2013-04-02 | Mark Pines | Composition and method for treating or preventing skeletal muscle fibrosis |
| AU2008329628B2 (en) * | 2007-11-30 | 2014-06-26 | The Regents Of The University Of California | Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine products |
| JP2011530596A (ja) * | 2008-08-11 | 2011-12-22 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | ｔＲＮＡ合成酵素の阻害のためのハロフジノン類似体およびそれらの使用 |
-
2013
- 2013-03-29 HK HK15107438.8A patent/HK1206646A1/xx unknown
- 2013-03-29 AU AU2013237881A patent/AU2013237881B2/en not_active Ceased
- 2013-03-29 CN CN201380027592.XA patent/CN104640546A/zh active Pending
- 2013-03-29 EP EP13770107.4A patent/EP2830628A4/en not_active Withdrawn
- 2013-03-29 WO PCT/US2013/034616 patent/WO2013149148A2/en not_active Ceased
- 2013-03-29 JP JP2015503640A patent/JP2015517994A/ja active Pending
- 2013-03-29 CA CA2869054A patent/CA2869054A1/en not_active Abandoned
- 2013-03-29 US US14/389,061 patent/US20150086627A1/en not_active Abandoned
-
2014
- 2014-09-28 IL IL234841A patent/IL234841A0/en unknown
-
2017
- 2017-09-20 US US15/709,725 patent/US20180193276A1/en not_active Abandoned
-
2018
- 2018-01-09 AU AU2018200167A patent/AU2018200167A1/en not_active Abandoned
- 2018-10-09 JP JP2018191024A patent/JP2018203790A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015517994A5 (enExample) | ||
| Stocchi et al. | Treatment of levodopa‐induced motor complications | |
| RU2014109074A (ru) | ИНГИБИТОРЫ ФАННИ-ТОКА (If), ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ В СПОСОБЕ ЛЕЧЕНИЯ И ПРЕДУПРЕЖДЕНИЯ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ У КОШАЧЬИХ | |
| Sullivan et al. | The Obalon swallowable 6-month balloon system is more effective than moderate intensity lifestyle therapy alone: results from a 6-month randomized sham controlled trial | |
| JP2011528333A5 (enExample) | ||
| IL259762A (en) | Complementary activity modulators | |
| JP2011225596A5 (enExample) | ||
| JP2018520189A5 (enExample) | ||
| EP2746251A3 (en) | Positively charged water-soluble prodrugs of acetaminophen and related compunds with very fast skin penetration rate | |
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| RU2012140704A (ru) | Способ профилактики и/или лечения фиброза и/или помутнения роговицы (варианты), способ получения фармацевтической композиции для профилактики и/или лечения фиброза и/или помутнения роговицы и глазная фармацевтическая композиция | |
| RU2014142267A (ru) | Лекарственное средство для лечения острого миелоидного лейкоза (омл) | |
| JP2016516016A5 (enExample) | ||
| JP2018509388A5 (enExample) | ||
| FI3746126T3 (fi) | Menetelmiä ja koostumuksia uniapnean tai pelkän kuorsauksen hoitamiseksi | |
| JP2017510607A5 (enExample) | ||
| JP2017501154A5 (enExample) | ||
| CN103298464A (zh) | 复方组合物 | |
| CN104640546A (zh) | 常山酮的剂型以及使用方法 | |
| EP3215132A1 (en) | Methods of administering amantadine compositions | |
| RU2015140572A (ru) | Способы лечения колоректального рака | |
| JP2016507500A5 (enExample) | ||
| PH12015502465A1 (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias | |
| RU2013108390A (ru) | Фармацевтическая композиция для предотвращения периоперационной артериальной гипотензии у человека | |
| JP2016512247A5 (enExample) |